BRCA2 and neoplasm: The potential to exploit this scenario became apparent when two independent studies reported dramatic cytotoxicity of PARP inhibitors in the context of deficiencies in the tumor suppressor genes BRCA1 and BRCA2 (breast cancer susceptibility genes 1 and 2) (Bryant et al. 2005; Farmer et al. 2005).